Hospital-acquired pneumonia: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 24: Line 24:
* [[Pulmonary embolism]]
* [[Pulmonary embolism]]
==Treatment==
==Treatment==
Usually initial therapy is empirical.<ref name="Harrison"/> If sufficient reason to suspect [[influenza]] one might consider [[amantadine]] or [[rimantadine]]. In case of [[legionellosis]] [[erythromicin]] or [[fluoroquinolone]].<ref name="Mandell"/>
Usually initial therapy is empirical. If sufficient reason to suspect [[influenza]] one might consider [[amantadine]] or [[rimantadine]]. In case of [[legionellosis]] [[erythromicin]] or [[fluoroquinolone]]. A third generation [[cephalosporin]] (ceftazidime) + [[carbapenems]] (imipenem) + beta lactam & beta lactamase inhibitors (piperacillin/tazobactum)


A third generation [[cephalosporin]] (ceftazidime) + [[carbapenems]] (imipenem) + beta lactam & beta lactamase inhibitors (piperacillin/tazobactum)
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 20:25, 5 September 2012

Pneumonia Main Page

Hospital-acquired pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hospital-Acquired Pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Diagnostic Algorithm

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hospital-acquired pneumonia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hospital-acquired pneumonia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hospital-acquired pneumonia

CDC onHospital-acquired pneumonia

Hospital-acquired pneumonia in the news

Blogs on Hospital-acquired pneumonia

Directions to Hospitals Treating Hospital-acquired pneumonia

Risk calculators and risk factors for Hospital-acquired pneumonia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hospital-acquired pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Treatment

Medical Therapy

Prevention

Differential diagnosis

Treatment

Usually initial therapy is empirical. If sufficient reason to suspect influenza one might consider amantadine or rimantadine. In case of legionellosis erythromicin or fluoroquinolone. A third generation cephalosporin (ceftazidime) + carbapenems (imipenem) + beta lactam & beta lactamase inhibitors (piperacillin/tazobactum)

References

Template:WH Template:WS